UBA3 and leukemia: Similarly, treatment-induced mutations of NAEβ/UBA3 were reported to lead to secondary resistance to MLN4924 in leukemia [30, 31], further mandating the development of combinational regiments including MLN4924 or novel next-generation NAE inhibitors.